Literature DB >> 26768481

Sarcopenia Is a Condition With Increasing Importance in Medical Oncology.

Umit Cintosun1, Battal Altun2, Ilker Tasci3.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26768481      PMCID: PMC4746095          DOI: 10.1634/theoncologist.2015-0431

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


× No keyword cloud information.
Sarcopenia has increasingly been proposed as a predictor of response to treatment in oncology patients. In the August 2015 issue of , Arrieta et al. reported that routinely screening for sarcopenia and nutritional status was helpful in determining the next step of chemotherapy as well as toxicities in patients with non-small cell lung cancer [1]. The authors specifically addressed the association of sarcopenia with afatinib-related gastrointestinal toxicity as an adverse effect. However, the results in this work seem to require some more discussion. In the study by Arrieta et al. [1], sarcopenia was assessed by computed tomography (L3 muscle index) based on the knowledge that it has high correlation with whole-body skeletal muscle mass. First, muscle mass estimation with computed tomography is a valuable option but it is not enough to identify sarcopenia correctly because the diagnosis of sarcopenia needs to be supported by clinical and laboratory measurements. Impaired muscle function and strength, which have gained significant importance in recent years, are also important components of sarcopenia according to a consensus report from the European Working Group on Sarcopenia in Older People [2, 3]. The group addressed not only muscle mass but also physical performance as assessed by gait speed, and grip strength measured by handheld dynamometer, to be used in an algorithmic workup to decide on the presence or absence of sarcopenia. Second, the fixed wide ranges of attenuation values for defining muscle mass area in the study by Arrieta et al. remain relatively broad, which can lead to false distinction of tissues [4]. Moreover, the fixed wide ranges of attenuation make it harder to differentiate between presarcopenia and sarcopenia. To sum up, although a decrease in muscle mass was detected in 68.8% of the participants, it is not actually evident what proportion the patients had true sarcopenia. Clarification of these issues may be relevant to the study results.
  4 in total

1.  Nutritional Status, Body Surface, and Low Lean Body Mass/Body Mass Index Are Related to Dose Reduction and Severe Gastrointestinal Toxicity Induced by Afatinib in Patients With Non-Small Cell Lung Cancer.

Authors:  Oscar Arrieta; Martha De la Torre-Vallejo; Diego López-Macías; David Orta; Jenny Turcott; Eleazar-Omar Macedo-Pérez; Karla Sánchez-Lara; Laura-Alejandra Ramírez-Tirado; Vickie E Baracos
Journal:  Oncologist       Date:  2015-07-14

2.  Sarcopenia is more than simply documenting low skeletal muscle mass.

Authors:  Umit Cintosun; Ilker Tasci; Vildan Binay Safer; Umut Safer
Journal:  Cancer       Date:  2014-09-10       Impact factor: 6.860

3.  Body composition and outcome in patients undergoing resection of colorectal liver metastases.

Authors:  M G van Vledder; S Levolger; N Ayez; C Verhoef; T C K Tran; J N M Ijzermans
Journal:  Br J Surg       Date:  2012-01-13       Impact factor: 6.939

4.  Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People.

Authors:  Alfonso J Cruz-Jentoft; Jean Pierre Baeyens; Jürgen M Bauer; Yves Boirie; Tommy Cederholm; Francesco Landi; Finbarr C Martin; Jean-Pierre Michel; Yves Rolland; Stéphane M Schneider; Eva Topinková; Maurits Vandewoude; Mauro Zamboni
Journal:  Age Ageing       Date:  2010-04-13       Impact factor: 10.668

  4 in total
  3 in total

1.  In Reply.

Authors:  Martha de la Torre-Vallejo; Jenny Turcott; Oscar Arrieta; Vickie Baracos
Journal:  Oncologist       Date:  2016-01-14

2.  Identifying sarcopenia in advanced non-small cell lung cancer patients using skeletal muscle CT radiomics and machine learning.

Authors:  Xing Dong; Xu Dan; Ao Yawen; Xu Haibo; Li Huan; Tu Mengqi; Chen Linglong; Ruan Zhao
Journal:  Thorac Cancer       Date:  2020-08-06       Impact factor: 3.500

3.  Body Composition in Patients with Radioactive Iodine-Refractory, Advanced Differentiated Thyroid Cancer Treated with Sorafenib or Placebo: A Retrospective Analysis of the Phase III DECISION Trial.

Authors:  Olivier Huillard; Anne Jouinot; Camille Tlemsani; Marcia S Brose; Jennifer Arrondeau; Gerold Meinhardt; Marc Fellous; Yoriko De Sanctis; Martin Schlumberger; Francois Goldwasser
Journal:  Thyroid       Date:  2019-12       Impact factor: 6.568

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.